College ter Beoordeling van Geneesmiddelen / Medicines Evaluation Board

Graadt van Roggenweg 500
3531 AH Utrecht
The Netherlands

DECENTRALISED PROCEDURE

PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT

Melosolute 5 mg/ml solution for injection for cattle, pigs, dogs and cats

Melosolute 20 mg/ml solution for injection for cattle, pigs, dogs and cats

NL/V/0164/001-002/DC

Created: October 2020

MODULE 1

PRODUCT SUMMARY

EU Procedure number	NL/V/0164/001-002/DC
Name, strength and pharmaceutical form	Melosolute 5 mg/ml solution for injection for cattle, pigs, dogs and cats Melosolute 20 mg/ml solution for injection for cattle, pigs, dogs and cats
Applicant	CP-Pharma Handelsgesellschaft mbH Ostlandring 13 D-31303 Burgdorf Germany
Active substance(s)	Meloxicam
ATC Vetcode	QM01AC06
Target species	Cattle, pigs, dogs and cats
Indication for use	**5 mg/ml:** Cattle**:** For use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle. For use in diarrhoea in combination with oral re-hydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle. For the relief of post-operative pain following dehorning in calves. Pigs**:** For use in non-infectious locomotor disorders to reduce the symptoms of lameness and inflammation. For the relief of post-operative pain associated with minor soft tissue surgery such as castration. Dogs**:** Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders. Reduction of post-operative pain and inflammation following orthopaedic and soft tissue surgery. Cats**:** Reduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery.

	20 mg/ml: Cattle: For use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle. For use in diarrhoea in combination with oral re-hydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle. For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy. For the relief of post-operative pain following dehorning in calves. Pigs: For use in non-infectious locomotor disorders to reduce the symptoms of lameness and inflammation. For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritis- agalactia syndrome) with appropriate antibiotic therapy. Horses: For use in the alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders. For the relief of pain associated with equine colic.

MODULE 2

The Summary of Product Characteristics (SPC) for this product is available on the Heads of Veterinary Medicines Agencies website (http://www.HMA.eu).

MODULE 3

PUBLIC ASSESSMENT REPORT

Legal basis of original application	Generic application in accordance with Article 13 (1)of Directive 2001/82/EC as amended.
Date of completion of the original decentralised procedure	25th April 2012
Date product first authorised in the Reference Member State (MRP only)	N/A
Concerned Member States for original procedure	Austria (withdrawn), Belgium (withdrawn), Czech Republic (withdrawn), Germany, Denmark (withdrawn), Spain (withdrawn), France, Hungary, Ireland (withdrawn), Italy (withdrawn), Poland (withdrawn), United Kingdom (withdrawn)

I. SCIENTIFIC OVERVIEW

The product is produced and controlled using validated methods and tests, which ensure the consistency of the product released on the market.
It has been shown that the product can be safely used in the target species; the slight reactions observed are indicated in the SPC.
The product is safe for the user, the consumer of foodstuffs from treated animals and for the environment, when used as recommended. Suitable warnings and precautions are indicated in the SPC.
The efficacy of the product was demonstrated according to the claims made in the SPC.
The overall risk/benefit analysis is in favour of granting a marketing authorisation.

Melosolute is authorized by means of a generic application. The reference product for Melosolute 5 mg/ml is Metacam 5 mg/ml Solution for Injection, authorized under number EU/2/97/004, and the reference product for Melosolute 20 mg/ml is Metacam 20 mg/ml Solution for Injection, authorized under number EU/2/97/004, by Boehringer Ingelheim Vetmedica GmbH.

II. QUALITY ASPECTS

A. Qualitative and quantitative particulars

Melosolute contains 5 mg/ml or 20 mg/ml of meloxicam.

The 5 mg/ml presentation contains the following excipients: ethanol, glycofurol, poloxamer 188, sodium chloride, glycine, meglumine and water for injection. Hydrochloric acid and sodium hydroxide are used for pH adjustment.

The 20 mg/ml presentation contain the following excipients: ethanol, macrogol 300, disodium edetate, poloxamer 188, glycine, meglumine and water for injection. Hydrochloric acid and sodium hydroxide are used for pH adjustment.

The solutions for injection are packed in clear, colourless type I glass vials, fitted with bromobutyl stoppers and aluminium caps. The glass vials and stoppers are in conformity with the Ph.Eur. requirements.

The products represent an established pharmaceutical form and their development is adequately described in accordance with the relevant European guidelines.

B. Method of Preparation of the Product

The products are manufactured fully in accordance with the principles of good manufacturing practice from a licensed manufacturing site.

The products are manufactured using conventional manufacturing techniques. Since the manufacturing process is a standard manufacturing process, the applicant commited to perform process validation on the first three post-marketing batches of each strength. The commitment has been fulfilled, process validation protocols and reports have been included.

The tests performed during production are described. Adequate in-process specifications are provided.

C. Control of Starting Materials

The active substance is meloxicam, an established active substance described in the European Pharmacopoeia. The active substance is manufactured in accordance with the principles of good manufacturing practice. The starting material is defined.

The active substance specification is considered adequate to control the quality of the material. The test methods are properly validated.
Batch analytical data demonstrating compliance with this specification have been provided.
The excipients are in conformity with compendial requirements. The only in-house specification for glycofurol shall be updated.
The glass vials and stoppers are in conformity with the Ph.Eur. requirements.
There are no substances within the scope of the TSE Guideline present or used in the manufacture of this product.

D. Control on intermediate products

Not applicable.

E. Control Tests on the Finished Product

The finished product specification controls the relevant parameters for the pharmaceutical form. The tests in the specification, and their limits, have been justified and are considered appropriate to adequately control the quality of the product.

Satisfactory validation data for the analytical methods have been provided.

Batch analytical data from the proposed production site have been provided demonstrating compliance with the specification.

F. Stability

Stability data on the active substance have been provided in accordance with applicable European guidelines, demonstrating the stability of the active substance when stored under the approved conditions.

Stability data on the finished products have been provided in accordance with applicable European guidelines, demonstrating the stability of all presentations throughout the claimed shelf life of 3 years without any special storage conditions.

The claim of a 28 days stability after broaching has been justified

G. Other Information

None.

III. SAFETY AND RESIDUES ASSESSMENT (PHARMACO-TOXICOLOGICAL)

As this is a generic application according to Article 13, and bioequivalence with a reference product has been demonstrated, results of pharmacological and toxicological tests are not required.

Warnings and precautions as listed on the product literature are the same as those of the reference product and are adequate to ensure safety of the product to users / the environment / consumers.

User Safety

The applicant has provided a user safety assessment in compliance with the relevant guideline which shows that accidental self-injection may give rise to pain. People with known hypersensitivity to Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) should avoid contact with the veterinary medicinal product.

Warnings and precautions as listed on the product literature are adequate to ensure safety to users of the product.

Environmental Risk Assessment

A Phase I environmental risk assessment (ERA) was provided according to the CVMP/VICH guidelines. The environmental risk assessment can stop in Phase I and no Phase II assessment is required because Melosolute 5 mg/ml will only be used in non-food animals, and Melosolute 20 mg/ml will be used to treat a small number of animals in a flock or herd.

III.B Residues documentation

Residue Studies

As this is a generic application according to Article 13, and bioequivalence with a reference product has been demonstrated, results of residue depletion studies are not required.

MRLs

Not applicable

Melosolute	NL/V/0164/001-002/DC
CP-Pharma Handelsges.mbH	DCP
	Publicly available assessment report

Withdrawal Periods

Based on the data provided above, a withdrawal period of:

- 15 days for meat and offal in cattle and 5 days for milk;
- 5 days for meat and offal in pigs;
- 5 days for meat and offal in horses

are justified.

IV. CLINICAL ASSESSMENT (EFFICACY)

As this is a generic application according to Article 13, and bioequivalence with a reference product has been demonstrated, efficacy studies are not required. The efficacy claims for this product are equivalent to those of the reference product.

V . OVERALL CONCLUSION AND BENEFIT– RISK ASSESSMENT

The data submitted in the dossier demonstrate that when the product is used in accordance with the Summary of Product Characteristics, the risk benefit profile for the target species is favourable and the quality and safety of the product for humans and the environment is acceptable.

MODULE 4

POST-AUTHORISATION ASSESSMENTS

The SPC and package leaflet may be updated to include new information on the quality, safety and efficacy of the veterinary medicinal product. The current SPC is available on the Heads of Vetrinary Medicines Agencies website (www.HMA.eu).

This section contains information on significant changes which have been made after the original procedure which are important for the quality, safety or efficacy of the product.

Summary of change	**Section updated**	**Approval date**
5 mg/ml: Extension of the shelf life of the finished product as packaged for sale (supported by real time data). (NL/V/0164/001/IB/001)	SPC	3 July 2013
5 mg/ml: Extension of the shelf life of the finished product, as packaged for sale (supported by real time data). (NL/V/0164/001/IB/002)	SPC	2 December 2013
20 mg/ml: Extension of the shelf life of the finished product, as packaged for sale (supported by real time data). (NL/V/0164/002/IB/003)	SPC	2 December 2013
5 mg/ml: New European Pharmacopoeial Certificate of Suitability to the relevant Ph. Eur. Monograph. from a new manufacturer. (NL/V/0164/001/IA/004)	N/A	17 February 2014
20 mg/ml: New European Pharmacopoeial Certificate of Suitability to the relevant Ph. Eur. Monograph. from a new manufacturer. (NL/V/0164/002/IA/005)	N/A	17 February 2014
Change(s) in the Summary of Product characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product. (NL/V/0164/001-002/IB/006)	SPC, Module 1 Indications	2 September 2015
Change(s) in the safety database and/or major contractual arrangements for the fulfilment of pharmacovigilance obligations, and/or change of the site undergoing pharmacovigilance activities.	N/A	18 November 2016

(NL/V/0164/001-002/IA/007)		
Renewal – NL as RMS (NL/V/0164/001-002/R/001)	N/A	12 January 2017
Update of an European Pharmacopoeial Certificate of Suitability to the relevant Ph. Eur. Monograph from an already approved manufacturer. New European Pharmacopoeial Certificate of Suitability to the relevant Ph. Eur. Monograph. from a new manufacturer. (NL/V/0164/001-002/IA/008/G)	N/A	29 November 2019
Update of an European Pharmacopoeial Certificate of Suitability to the relevant Ph. Eur. Monograph from an already approved manufacturer. Deletion of a manufacturing site of an active substance (NL/V/0164/001-002/IA/009/G)	N/A	30 October 2020
Change in the batch size of the finished product (NL/V/0164/001-002/IB/010)	N/A	1 May 2021
20 mg/ml: Change in the batch size of the finished product (NL/V/0164/002/A/011)	N/A	5 August 2023